Sorry, you need to enable JavaScript to visit this website.
Skip to main content
Home

Header Top Menu

  • News & Featured Stories
  • Media
  • Careers
  • Contact Us
  • Our Science

    Sub Menu 1

    • Pfizer in the UK
      • Our History
      • Pharmaceutical Sciences
      • Devices Centre of Excellence
      • Global Regulatory Affairs
      • Material Characterisation Team
      • Anti-Counterfeit Laboratory
    • Our Therapy Areas
      • Anti-Infectives
      • Inflammation and Immunology
      • Internal Medicine
      • Oncology
      • Rare Disease
      • Vaccines

    Sub Menu 2

    • Developing New Medicines
      • Clinical Trials
      • Pipeline
    • Research partnerships
      • ADDoPT
      • Innovative Target Exploration Network (ITEN)
      • INSPIRE Programme
      • Medical Research Council Collaboration
      • The Stratified Medicine Programme
      • Partnership with Regeneron for UK Biobank exome sequencing
    • Breakthroughs that change patients’ lives
    Hot Topic

    Re-shaping Cancer

    Re-shaping cancer
  • Products

    Sub Menu 4

    • Prescription medicines

    Sub Menu 5

    • Safety of Medicines
      • Medicines Regulation
      • Reporting Side Effects
      • Counterfeit Medicines
    Hot Topic

    Vaccines partnerships

    Vaccines partnerships
  • Responsibility

    Sub Menu 7

    • Transparency
      • HCP & HCO Annual Disclosure Reports
      • Healthcare Organisation Grants
      • Research and Development Funding
      • Patient Organisation Funding and Support
    • Codes of Conduct
      • Gender Pay Gap Report
      • Section 172 Statements
      • Pfizer UK Modern Slavery Statement
      • Pfizer UK Tax Strategy

    Sub Menu 8

    • Environmental Sustainability
      • Climate Action
      • Global Actions
      • Our Partnerships & Commitments
      • Sustainable Medicines
      • UK Actions
    • Insurance Details
    • Animal Welfare
    Hot Topic

    Putting Patients First

    Putting Patients First
  • UK Society

    Sub Menu 10

    • Social Investment
      • Volunteering and Fundraising
      • Medicines Donations
    • Raising Public Awareness
      • Change the Course
      • Pfizer Sponsors Science Museum Group's 'Cancer Revolution' Exhibition
      • Pfizer Sponsors the Superhero Series
      • Pfizer sponsors Science Museum exhibition 'Superbugs'
      • Pfizer at the British Science Festival
      • Turning Heads at Westminster

    Sub Menu 11

    • Science Education
      • Developing Science Talent
      • 'Superbugs Join The Fight' School Programme
      • Online Learning
        • Student Education Area
        • Teacher Resources
      • Community Lab
      • Career Talks
      • Lab in a Box
    • Pfizer Worldwide
      • Global Health Fellows
      • Global Aid and Emergency Relief
      • International Trachoma Initiative
    Hot Topic

    'Superbugs' Competition Winners

    Superbugs Winners
  • UK Health System

    Sub Menu 16

    • Working with the NHS and other Healthcare Organisations
      • Collaborative Working
        • Collaborative Working Project between Lloyds Pharmacy and Pfizer Vaccines
        • Joint Working
      • Donations and Grants
        • Independent Medical Grants and Donations
        • Donations of Goods, Services and Benefit in Kind
        • Grants
        • Donations and Grants Enquiry Form
    • Working with Healthcare Professionals
      • FAQs: Working with Healthcare Professionals
      • Pharmacy
      • Healthcare Professionals Congress Sponsorship

    Sub Menu 17

    • Working with Patient Organisations
      • Patient Involvement in Research and Development
      • Our ongoing partnership with the UK Sepsis Trust
      • Partnering with the NIHR and young people on clinical research
    • Pfizer Healthcare Hub
      • Pfizer Healthcare Hub: 2018
      • Pfizer Healthcare Hub: 2017
      • Connect with the Hub
    Hot topic

    Osteoarthritis

    Osteoarthritis
  • News & Featured Stories
  • Media
  • Careers

    Carrers

    • Search Current Vacancies
    • Apprenticeships
      • Apprenticeship Vacancies
    • Undergraduate Placements
      • Undergraduate Vacancies
    • Meet our people
    • UK Top Employer
    • How Pfizer is fostering meaningful growth for every colleague, everywhere
  • Contact Us
  • Footer links

    Footer mobile menu

    • Footer Menu
    • Footer menu
      • Contact Us
      • Cookie Policy
      • Terms of Use
      • Privacy Policy
      • Sitemap
    • Footer social item
      • Facebook
      • Twitter
      • Instagram
      • YouTube

Innovation Is Coming: Let's Embrace It Together

Innovation Is Coming: Let's Embrace It Together
News & Featured Stories/ Innovation Is Coming: Let's Embrace It Together
12/03/2019

Owen Marks
Head of Rare Diseases, Pfizer UK

In 2003 the first human genome was sequenced.1 This major milestone enabled scientists to further understand how they could diagnose and treat genetic disorders. Now, sixteen years on, we are standing on the brink of a new era of innovation. But bringing this innovation to patients won’t be easy. For this to be realised it will require industry, Government, and the NHS all working in a renewed partnership to seize the opportunity and make it happen for patients.

 

Since I started working in the pharmaceutical industry over twenty years ago, I could never have imagined then how far we would come in advancing our science and medical innovation in supporting and treating patients. Where I work in rare diseases, this innovation has the potential to be most felt. Rare diseases are individually rare but collectively common, and their impact is widespread, with over 3.5 million people in the UK affected.2 Globally, of the 7,000 known rare diseases almost 80%, or 6,000, are genetic diseases.3

Gene therapy is one such treatment that offers so much potential to patients with rare conditions. It is an experimental technique that can target these rare diseases and fixes the ‘faulty’ genes that cause illnesses. Unlike other treatments which often require frequent administration and focus on managing symptoms and disease progression, gene therapy aims to fix what is not working and provide a long-term treatment.

 

There is a real opportunity here for us to embrace a renewed partnership and together deliver the treatment a generation of patients need." 

For patients this could mean they no longer experience the debilitating symptoms their rare disease brings, and their life expectancy and quality of life could improve. For the NHS it could help to reduce the strain on the healthcare system and allow people who were previously too ill, to play a more active role in society.

Gene therapy and other new innovative treatments are symbolic of the great potential, but also the challenges we face. With a current healthcare system geared towards more common conditions, how do we rebalance it to deal with the generation of millions of patients with thousands of different rare diseases? For me, we need to set in place the right framework across the systems and pathways to enable patients to get the right treatment, at the right time, in the right way.

The critical first step is to come together in a renewed partnership. We have an opportunity to work together to future proof the ‘system’ by discussing the challenges and opportunities in bringing innovation, combined with the right care pathway for these patients. The NHS Long Term Plan has set in place some positive foundations for us to achieve this, but we now just need to ensure that these advancements in science and medical innovation, that have been hard fought, will be able to reach the patients that need them.

At Pfizer we’re committed and passionate about playing our part. There is a real opportunity here for us to embrace a renewed partnership and together deliver the treatment a generation of patients need.

 

References

  1. National Human Genome Research Institute. Human Genome Project FAQ Accessed Nov 2021.
  2. Global Genes. Rare Disease Impact Report  (Shire, April 2013) Accessed Nov 2021.
  3. Global Genes. Rare Disease Facts Accessed Nov 2021.

 

PP-PFE-GBR-4229 / November 2021

Related Hot Topics
What is a Variant
What is a Variant?
Patients at heart of clinical trials
Why putting patients at the heart of Pfizer UK’s clinical trials continues to…
AMR Explained
Antimicrobial Resistance Explained
Infection Management Coalition Paper
Cross-Industry Coalition Tackling ‘Hidden Pandemic’ of Antibiotic Resistant…
Maternal Immunisation
Protecting Babies from Inside the Womb
Blueprint for gene therapy adoption
Pfizer UK launch blueprint for the UK adoption of cell and gene therapies
Protease Inhibitor
How Does a Protease Inhibitor Work?
Gene Sequencing
How Gene Sequencing Inaugurated a New Era in Modern Medicine
Tags
Science / R&D
Rare Diseases

Footer

  • Contact Us
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Sitemap

Footer aside

  • Footer Aside
    • Facebook
    • Twitter
    • Instagram
    • YouTube

Copyright © 2017-2022 Pfizer Limited. PP-PFE-GBR-4248 / Nov 2021. All rights reserved. Registered in England and Wales No. 526209. Registered office: Ramsgate Road, Sandwich, Kent CT13 9NJ. VAT No. GB201048427